Skip to main content
. 2019 Oct 1;8(16):6955–6966. doi: 10.1002/cam4.2555

Figure 1.

Figure 1

Patient disposition. Patient disposition during induction therapy with RBMD. *1 patient who showed progressive disease during the first RBMD cycle died. **1 patient died due to grade 5 infection (CMV reactivation in the context of influenza A sepsis). 8 patients were withdrawn due to toxicity, including five patients withdrawn due to treatment delays >4 wk. CR, complete response; PD, progressive disease; PR, partial response; RBMD, rituximab, bendamustine, mitoxantrone, and dexamethasone; SD, stable disease; uCR, unconfirmed complete response